GERN: Geron Corp
Performance
GERN -6.87%
Watchlist
Select an item
Summary
GERN at a glance
GERN returned -6.87% over the past year and -9.57% a year over five years. Its worst drop in that year was -54.13%, smaller than 18% of stocks on Redstone, and its Sharpe ratio of 0.18 beats 35% of stocks on Redstone. It pays no dividends.
Current Drawdown
-48.90%
Rolling Volatility
99.32%
Actions
Metrics
Risk Indicators
Alpha-2.73%
Beta1.51x
Sharpe0.18
Sortino0.27
Omega1.03
Calmar-0.13
Martin0.48
Profile
About GERN
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $640M
- Listed
- Jul 1996
- Employees
- 258
- Headquarters
- Foster City, CA
- Website
- geron.com
Comparisons